))
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
Manage episode 414856478 series 3381434
Contenu fourni par ReachMD. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par ReachMD ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/navigating-treatment-related-adverse-effects-in-lag-3-combination-ici-therapy-for-metastatic-melanoma/24367/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
…
continue reading
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/navigating-treatment-related-adverse-effects-in-lag-3-combination-ici-therapy-for-metastatic-melanoma/24367/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
667 episodes
Partager
